Brookline downgraded Dare Bioscience to Hold from Buy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DARE:
- Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
- Dare Bioscience announces publication of data from Ovaprene study
- Daré Bioscience’s Reverse Stock Split: Navigating the Risks of Market Perception and Shareholder Liquidity
- Dare Bioscience files to sell 15M shares of common stock for holders
- Dare Bioscience files $200M mixed securities shelf